MedPod Today: Medicare Advantage Woes, Double Billing, NHPI Health Disparities
<em>MedPage Today</em> reporters offer further insights on these recently covered topics
Source: medpagetoday.com
📰 Greg Laub News
Page 2 - Greg Laub News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Greg Laub. Real-time updates on events, politics, business and more.
MedPod Today: Residency Application Updates; Doc Discipline; Vacation and Burnout
<em>MedPage Today</em> reporters offer further insights on these recently covered topics
Source: medpagetoday.com
Questions Remain on ADC Sequencing in Metastatic Breast Cancer
Yuan Yuan, MD, discusses the need for evidence-based answers in 2024
Monica Mita Los Angeles Greg Laub Sinai Cancer Center San Antonio Breast Cancer Symposium Cedars Sinai Cancer Center
Source: medpagetoday.com
Novel Combination Active in Large B-Cell Lymphoma, Even After CAR-T
But where mosunetuzumab/polatuzumab vedotin would fit among available options remains a question
United States Yazeed Sawalha Greg Laub Kami Maddocks David Bond Ohio State University Wexner Medical Center
Source: medpagetoday.com
Pirtobrutinib Shows Potential in Heavily Pretreated Follicular Lymphoma
'Safety profile is one of the real advantages' of non-covalent BTK inhibitor, says panelist
Source: medpagetoday.com
PD-L1 Subgroup Benefits Most From Neoadjuvant Immunotherapy in Early Breast Cancer
Lajos Pusztai reviews the two 'potentially paradigm-shifting trials'
San Antonio United States New Haven Greg Laub Yale School Of Medicine San Antonio Breast Cancer Symposium
Source: medpagetoday.com
Liso-Cel a Potential New CAR-T Option for High-Risk R/R Follicular Lymphoma
Study results show impressive efficacy, favorable safety profile in the second line
United States Greg Laub Kami Maddocks David Bond Yazeed Sawalha Ohio State University Wexner Medical Center
Source: medpagetoday.com
Axi-Cel Shows Durable Responses, Prolongs Overall Survival in Older LBCL Patients
Our panel discusses findings from the ZUMA-12 study and the ZUMA-7 study
Source: medpagetoday.com
Dato-DXd More Effective, Tolerable Than Chemo for Metastatic Breast Cancer
But sequencing of ADCs such as datopotamab deruxtecan remains an unanswered question
United States San Antonio Jasmine Singh Sukumar Greg Laub University Of Texas Md Anderson Cancer Center San Antonio Breast Cancer Symposium
Source: medpagetoday.com
Chemo-Free Quadruplet Promising as Initial Treatment in DLBCL
Approach could allow for a response-adapted reduction of CHOP
United States Kamij Maddocks Greg Laub Yazeedy Sawalha American Society Of Hematology Ohio State University Wexner Medical Center
Source: medpagetoday.com